ArticleHaematologica2017

Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the

Lionel Ades et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.